Artisan Partners Limited Partnership Increases Holdings in LivaNova PLC $LIVN

Artisan Partners Limited Partnership increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 94.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,427,045 shares of the company’s stock after purchasing an additional 1,179,436 shares during the quarter. Artisan Partners Limited Partnership owned approximately 4.45% of LivaNova worth $127,129,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. State of Wyoming bought a new position in LivaNova in the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its position in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the last quarter. UMB Bank n.a. grew its stake in LivaNova by 63.0% during the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after acquiring an additional 306 shares in the last quarter. Bayforest Capital Ltd increased its holdings in LivaNova by 44.8% in the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock valued at $48,000 after acquiring an additional 284 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in LivaNova by 90.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,202 shares of the company’s stock valued at $63,000 after acquiring an additional 572 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several research reports. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Barclays increased their price target on LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research note on Friday. Mizuho lifted their price objective on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. KeyCorp assumed coverage on LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 target price for the company. Finally, Robert W. Baird set a $75.00 price target on shares of LivaNova in a research report on Tuesday, December 16th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and a consensus target price of $74.78.

LivaNova Price Performance

Shares of LivaNova stock opened at $70.60 on Friday. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -15.83 and a beta of 0.97. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.12 and a current ratio of 1.36. The stock has a 50 day moving average price of $64.74 and a 200-day moving average price of $59.04. LivaNova PLC has a one year low of $32.48 and a one year high of $71.92.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. The company had revenue of $360.86 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.